{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-021379","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2025-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.715833+00:00","generated_at":"2026-05-25T08:28:47.172302+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Theriva Biologics FY2024 cash $11.6M; VCN-01 Phase 2b data due Q2 2025","bullets":["Cash and cash equivalents $11.6M as of Dec 31, 2024; expected runway into Q3 2025.","R&D expenses decreased 16% to $12.0M; G&A expenses increased 4% to $7.4M.","VIRAGE Phase 2b enrollment completed (92 evaluable patients); topline data expected Q2 2025.","FDA Fast Track for VCN-01 in PDAC; FDA and EMA provided Phase 3 trial design guidance.","Audited 10-K includes going concern explanatory paragraph from independent auditor."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-021379","json":"https://secwatch.observer/filing/0001104659-25-021379.json","markdown":"https://secwatch.observer/filing/0001104659-25-021379.md","text":"https://secwatch.observer/filing/0001104659-25-021379.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465925021379/0001104659-25-021379-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465925021379/tm258283d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T08:28:47.172302+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}